Previous Close | 2.2400 |
Open | 2.2500 |
Bid | 2.2400 x N/A |
Ask | 2.2800 x N/A |
Day's Range | 2.2300 - 2.2850 |
52 Week Range | 1.3500 - 3.9500 |
Volume | |
Avg. Volume | 237,560 |
Market Cap | 232.263M |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.5100 |
Earnings Date | Aug 02, 2024 - Aug 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.77 |
Announced today that it has completed an early partial funding of its final third tranche investment ...
TORONTO, July 24, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has completed an early partial funding of its final third tranche investment into Phylos Bioscience Inc. ("Phylos"), a U.S. cannabis genetics company and provider of production ready seeds, with the remaining portion of the final tranche to be funded upon completion of the newly expanded final milestone.
North American cannabis firms, facing prohibitive laws, an overcrowded market and a deeply entrenched illicit sector at home are ramping up investments in Germany after the country partly legalized marijuana use. Germany, the largest medical cannabis market in Europe, decriminalized cannabis possession and small-scale home cultivation in April, making it easier for doctors to prescribe it. But only a few local companies are licensed to grow pot, and U.S. and Canadian firms are looking to capture a slice of the market by providing capital and exporting products to Germany.